Axillary lymphadenectomy is the standard of care in @entity0 @entity1 . Lymphatic mapping has arisen as an alternative offering less morbidity. OBJECTIVE: To determine the success rate of subareolar blue dye injection (SM) in @entity1817 ( @entity1817 ) biopsy and its value in axillary staging. METHODS: 62 stages I and II @entity0 @entity1 without palpable axillary nodes received subareolar injection of blue dye; an intraoperative study of the @entity1817 was carried out. Axillary lymphadenectomy was carried out in all @entity1 . Sensitivity, specificity, positive predictive value, and negative predictive value were measured. RESULTS: In 58/62 @entity1 (93.5%), @entity1817 was identified; 19/58(32%) @entity1 had nodal metastases, 18 were identified in intraoperative study, and only one false negative; 12/18 @entity1 showed @entity3 in other axillary nodes (66%), in 6 (27%) the only @entity3 site was @entity1817 . Sensitivity/specificity of the @entity1817 was 92.8 and 88.6%, respectively. Positive predictive value is 72.2% and negative predictive value is 97.5% CONCLUSION: SAI of blue dye allows identification of @entity1817 in 93.5%; with high sensitivity. @entity1817 negative predictive value is 97.5% in this study.

[lymphatic Mapping and Sentinel Lymph Node Biopsy in @entity1 with XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1817 :: ('MESH:D012804', 'Disease') :: ['SN', 'sentinel node'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']
@entity0 :: (MESH:D001943,Disease) :: ['Breast Cancer']
